MicroRNAs in Patients With Neurofibromatosis Type 1
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Other Indications, Brain Cancer |
| Therapuetic Areas: | Oncology, Other |
| Healthy: | No |
| Age Range: | 2 - 21 |
| Updated: | 4/21/2016 |
| Start Date: | February 2012 |
| End Date: | July 2015 |
MicroRNAs as Disease Markers for Central Nervous System Tumors in Patients With Neurofibromatosis Type 1
MicroRNAs are small molecules which have recently been discovered in cells. They are known
to be responsible for the normal development of cells and when they are disrupted can
contribute to the development of cancer. Many previous studies have been done evaluating the
expression of microRNAs in normal tissues as well as in a wide variety of cancers.
Recently, microRNAs from tumor cells have been detected circulating in the blood of patients
with cancer. This presents a novel opportunity to assess the utility of microRNAs in the
blood as an early predictor of cancer as well as a marker of response to therapy. No
previous studies have been performed evaluating microRNAs in archived tumor tissue and blood
of patients with Neurofibromatosis type 1 (NF-1). The investigators propose a feasibility
study to evaluate the presence of microRNAs in archived tumor tissue and the blood of
patients with NF-1. If the investigators are able to identify circulating microRNAs in this
population of pediatric patients, they will build upon this data in proposing a future
study.
to be responsible for the normal development of cells and when they are disrupted can
contribute to the development of cancer. Many previous studies have been done evaluating the
expression of microRNAs in normal tissues as well as in a wide variety of cancers.
Recently, microRNAs from tumor cells have been detected circulating in the blood of patients
with cancer. This presents a novel opportunity to assess the utility of microRNAs in the
blood as an early predictor of cancer as well as a marker of response to therapy. No
previous studies have been performed evaluating microRNAs in archived tumor tissue and blood
of patients with Neurofibromatosis type 1 (NF-1). The investigators propose a feasibility
study to evaluate the presence of microRNAs in archived tumor tissue and the blood of
patients with NF-1. If the investigators are able to identify circulating microRNAs in this
population of pediatric patients, they will build upon this data in proposing a future
study.
Inclusion Criteria:
- Patients ages 2 years to 21 years.
- Patients with NF-1 being followed in the Neurofibromatosis Clinic.
- Patients have had MRI imaging in the 24 months prior to enrollment on the study.
- Patients may have known concurrent malignancies such as plexiform neurofibroma.
- Patients and/or parents/legal guardians must have signed an informed consent and
assent when applicable.
Exclusion Criteria:
- Patients who have had prior tumor-directed therapy (including chemotherapy and/or
radiation)
- Patients with a prior or current diagnosis of a malignant peripheral nerve sheath
tumor.
- Patients who are considered too ill to participate as determined by their treating
physician
- Patients who are pregnant or lactating
We found this trial at
1
site
225 E Chicago Ave
Chicago, Illinois 60611
Chicago, Illinois 60611
(312) 227-4000
Ann & Robert H. Lurie Children's Hospital of Chicago Ann & Robert H. Lurie Children
Click here to add this to my saved trials
